Outgoing FDA chief Gottlieb taking drug price fight to think tank

Scott Gottlieb FDA
Scott Gottlieb said his primary focus at the American Enterprise Institute will be finding affordable solutions for innovative treatments, including gene therapy. (FDA)

As FDA commissioner, Scott Gottlieb battled to lower the cost of prescription drugs and streamline approval of biosimilars. Now, Gottlieb is taking that fight to the private sector.

In an interview with The Washington Post, Gottlieb, who will leave the Trump administration Friday, said he plans to take a fellowship with conservative think tank American Enterprise Institute (AEI) to continue pushing for lower prices and faster approval of biologics.

Gottlieb said his primary focus at AEI will be finding affordable solutions for innovative treatments, including gene therapies.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

“The question is, how do we spread out those costs?” he told the newspaper. “That’s a whole different paradigm.”

Prior to his confirmation as FDA chief in May 2017, Gottlieb served as resident fellow at AEI and held various consulting and board positions for pharma and medical device companies.

After joining the FDA, Gottlieb quickly went to bat on lowering the cost of drugs and boosting competition.

RELATED: New FDA commissioner Gottlieb unveils price-fighting strategies

In late May 2017, he unveiled an ambitious plan to publish and regularly update a list of medications that are off patent and have no competition, work to improve generic review times and seek to “curtail gaming” of regulations by the branded industry that limits competition.

Although the FDA has no oversight over patenting, Gottlieb also pointed a finger at drugmakers for litigating patents to delay biosimilar uptake. In July 2018, he said some tactics the industry uses "should be unacceptable to every member of the drug supply chain.”

RELATED: FDA chief Gottlieb blames drugmakers for ‘anemic’ biosimilar market

“We’re not going to play regulatory whack-a-mole with companies trying to unfairly delay or derail the entry of biosimilar competitors,” Gottlieb said in a prepared speech at a Brookings Institution event. “We’re not going to wait a decade or more for robust biosimilar competition to emerge.”

In December, following up on his pledge to lower drug prices, Gottlieb outlined a plan to reclassify insulin from a drug to a biologic, opening the door for biosimilar competition that would—theoretically—cut the cost of prescription insulin.

RELATED: FDA Commissioner Scott Gottlieb blasts insulin pricing, unveils move to bolster biosimilar competition

“There are currently no approved insulin products that can be substituted at the pharmacy level," he said, according to prepared remarks at a CMS summit. "One reason is that it was hard to bring a substitutable generic insulin to the market under the conventional drug pathway. The biosimilar pathway should make this kind of competition more accessible.” 

Gottlieb will resign Friday without seeing that plan come to fruition, saying in December that he wanted the FDA to reclassify insulin in March 2020.

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.